MedTrace Logo

Viagra in the Treatment of Primary Dysmenorrhea

NCT00123162 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2015-12-23

Study results available
· View outcomes & findings →

Summary

The primary hypothesis is that a 100mg single dose of sildenafil citrate (Viagra) will have a higher improvement rate when compared to placebo in the treatment of moderate to severe primary dysmenorrhea.

Conditions

  • Dysmenorrhea

Interventions

DRUG

Sildenafil Citrate

A single vaginal dose of sildenafil citrate 100 mg and monitored for 4 hours.

DRUG

Placebo

A single vaginal dose of placebo and monitored for 4 hours.

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • Milton S. Hershey Medical Center

    lead OTHER

Principal Investigators

  • Richard Legro, M.D. · Penn State University College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2011-06-30
Completion
2011-08-31

Countries

  • Croatia

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00123162 on ClinicalTrials.gov